Lilly's Pain Is Biotech's Gain After CETP Failure
This article was originally published in Scrip
Executive Summary
The failure of Eli Lilly & Co.'s cholesterol drug evacetrapib was a major blow to the company and will likely be a hit to Merck & Co. as well, but it wasn't a loss for everyone – Amgen Inc, Regeneron Pharmaceuticals Inc and Sanofi stand to make major gains from the loss.